PURPOSE: The Forkhead transcription factors (FOXO) are tumor suppressor genes regulating differentiation, metabolism, and apoptosis that functionally interact with signal transduction pathways shown to be deregulated and prognostic in acute myelogenous leukemia (AML). This study evaluated the level of expression and the prognostic relevance of total and phosphorylated FOXO3A protein in AML. EXPERIMENTAL DESIGN: We used reverse-phase protein array methods to measure the level of total and phosphoprotein expression of FOXO3A, in leukemia-enriched protein samples from 511 newly diagnosed AML patients. RESULTS: The expression range was similar to normal CD34+ cells and similar in blood and marrow. Levels of total FOXO3A were higher at relapse compared with diagnosis. Levels of pFOXO3A or the ratio of phospho to total (PT) were not associated with karyotpe but were higher in patients with FLT3 mutations. Higher levels of pFOXO3A or PT-FOXO3A were associated with increased proliferation evidenced by strong correlation with higher WBC, percent marrow, and blood blasts and by correlation with higher levels of Cyclins B1, D1 and D3, pGSK3, pMTOR, and pStat5. Patients with High levels of pFOXO3A or PT-FOXO3A had higher rates of primary resistance and shorter remission durations, which combine to cause an inferior survival experience (P = 0.0002). This effect was independent of cytogenetics. PT-FOXO3A was a statistically significant independent predictor in multivariate analysis. CONCLUSIONS: High levels of phosphorylation of FOXO3A is a therapeutically targetable, independent adverse prognostic factor in AML.
PURPOSE: The Forkhead transcription factors (FOXO) are tumor suppressor genes regulating differentiation, metabolism, and apoptosis that functionally interact with signal transduction pathways shown to be deregulated and prognostic in acute myelogenous leukemia (AML). This study evaluated the level of expression and the prognostic relevance of total and phosphorylated FOXO3A protein in AML. EXPERIMENTAL DESIGN: We used reverse-phase protein array methods to measure the level of total and phosphoprotein expression of FOXO3A, in leukemia-enriched protein samples from 511 newly diagnosed AMLpatients. RESULTS: The expression range was similar to normal CD34+ cells and similar in blood and marrow. Levels of total FOXO3A were higher at relapse compared with diagnosis. Levels of pFOXO3A or the ratio of phospho to total (PT) were not associated with karyotpe but were higher in patients with FLT3 mutations. Higher levels of pFOXO3A or PT-FOXO3A were associated with increased proliferation evidenced by strong correlation with higher WBC, percent marrow, and blood blasts and by correlation with higher levels of Cyclins B1, D1 and D3, pGSK3, pMTOR, and pStat5. Patients with High levels of pFOXO3A or PT-FOXO3A had higher rates of primary resistance and shorter remission durations, which combine to cause an inferior survival experience (P = 0.0002). This effect was independent of cytogenetics. PT-FOXO3A was a statistically significant independent predictor in multivariate analysis. CONCLUSIONS: High levels of phosphorylation of FOXO3A is a therapeutically targetable, independent adverse prognostic factor in AML.
Authors: Carlos M Santamaría; Maria C Chillón; Ramón García-Sanz; Cristina Pérez; María D Caballero; Fernando Ramos; Alfonso García de Coca; José M Alonso; Pilar Giraldo; Teresa Bernal; José A Queizán; Juan N Rodriguez; Pascual Fernández-Abellán; Abelardo Bárez; María J Peñarrubia; María B Vidriales; Ana Balanzategui; María E Sarasquete; Miguel Alcoceba; Joaquín Díaz-Mediavilla; Jesús F San Miguel; Marcos Gonzalez Journal: Leuk Res Date: 2009-05-19 Impact factor: 3.156
Authors: Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills Journal: Blood Date: 2008-10-07 Impact factor: 22.113
Authors: Rosaline C-Y Hui; Ana R Gomes; Demetra Constantinidou; Joana R Costa; Christina T Karadedou; Silvia Fernandez de Mattos; Matthias P Wymann; Jan J Brosens; Almut Schulze; Eric W-F Lam Journal: Mol Cell Biol Date: 2008-07-21 Impact factor: 4.272
Authors: Yiyu Zou; Wen-Bin Tsai; Chien-Jui Cheng; Chiun Hsu; Young Min Chung; Pao-Chen Li; Sue-Hwa Lin; Mickey C T Hu Journal: Breast Cancer Res Date: 2008-02-29 Impact factor: 6.466
Authors: Deepa Sampath; Asifa Malik; William Plunkett; Billie Nowak; Betsy Williams; Michelle Burton; Srdan Verstovsek; Stefan Faderl; Guillermo Garcia-Manero; Alan F List; Said Sebti; Hagop M Kantarjian; Farhad Ravandi; Jeffrey E Lancet Journal: Leuk Res Date: 2013-08-06 Impact factor: 3.156
Authors: Shan Lin; Anetta Ptasinska; Xiaoting Chen; Mahesh Shrestha; Salam A Assi; Paulynn S Chin; Maria R Imperato; B J Aronow; Jingsong Zhang; Matthew T Weirauch; Constanze Bonifer; James C Mulloy Journal: Blood Date: 2017-07-14 Impact factor: 22.113
Authors: Peter P Ruvolo; Vivian R Ruvolo; Rodrigo Jacamo; Jared K Burks; Zhihong Zeng; Seshagiri R Duvvuri; Liran Zhou; Yihua Qiu; Kevin R Coombes; Nianxiang Zhang; Suk Y Yoo; Rongqing Pan; Numsen Hail; Marina Konopleva; George Calin; Steven M Kornblau; Michael Andreeff Journal: Biochim Biophys Acta Date: 2014-05-21
Authors: Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff Journal: Biochim Biophys Acta Mol Cell Res Date: 2018-04-12 Impact factor: 4.739
Authors: Jill S Butler; Yi Hua Qiu; Nianxiang Zhang; Suk-Young Yoo; Kevin R Coombes; Sharon Y R Dent; Steven M Kornblau Journal: Leuk Lymphoma Date: 2016-10-13
Authors: L Quotti Tubi; S Canovas Nunes; A Brancalion; E Doriguzzi Breatta; S Manni; E Mandato; F Zaffino; P Macaccaro; M Carrino; K Gianesin; L Trentin; G Binotto; R Zambello; G Semenzato; C Gurrieri; F Piazza Journal: Leukemia Date: 2016-08-01 Impact factor: 11.528
Authors: Julien van Grevenynghe; Rafael A Cubas; Sandrina DaFonseca; Talibah Metcalf; Cecile L Tremblay; Lydie Trautmann; Rafick-Pierre Sekaly; John Schatzle; Elias K Haddad Journal: Cytokine Growth Factor Rev Date: 2012-06-27 Impact factor: 7.638